How to Evaluate Fertility Centers, Hypoandrogenic PCOS & More: June 2018 VOICE is here!

The June issue of the VOICE is traditionally the last before a summer hiatus in July and August, unless, of course, important news must be immediately conveyed to our readership. In recent years, this meant that we never really succeeded in breaking publication of this newsletter for both months. At best, we were able to take off for one month in either July or August. The intent this year, however, is, one again, to try for the full two months, and return rested and with vengeance in September. Let’s see whether we can pull it off this year.

In the meantime, we, however, wish all patients, colleagues and other readers of the VOICE that their summer be better than the non-existent spring we just experienced. Like everywhere else, the summer months are the principal vacation time for most of our staff. For those remaining behind, the workload, therefore, is quite significant since the two summer months are usually quite busy. Especially long-distance patients often choose to use their vacation time to undergo treatments at CHR. If you have not already done so, for those of you who are considering a cycle during the summer at CHR, now is the time to let us know. Because CHR serves so many long-distance patients, CHR’s services will continue uninterrupted.

Our lead article this month is about the Polycystic Ovary Syndrome (PCOS), considered by many the single most frequent cause of female infertility. CHR investigators in recent years discovered, described and elucidated important underlying mechanisms of a new PCOS-like phenotype they gave the name hypo-androgenic PCOS (H-PCOS). Though two papers in prestigious medical journals described this new phenotype in very much detail [Gleicher et al., J Steroid Biochem Mol Biol 2017;167:144-152 and Gleicher et al., Endocrine 2018 2018;59(3)661-676], it is still not widely enough known among colleagues. We, therefore, hope that the review presented in this issue will attract further attention not only from patients but also from colleagues who never before heard about H-PCOS. Once familiar with the clinical presentation of this phenotype, colleagues will be surprised (as CHR physicians were) how frequent this phenotype is in women with repeated IVF failures, and how simple it is to change the prognosis of so-affected patients.

In this issue, we cover:

Read this issue of the CHR VOICE in PDF.

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned reproductive endocrinologist, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.